Company Profile

Sunniva is an ancient English name which means "Gift of the Sun."

Strategic assets are in place to become one of the lowest cost operators, producing pesticide-free premium quality cannabis products, and achieving true vertical integration in California by:

  • Producing our own Sunniva branded products for the California market
  • Leveraging our large-scale mega efficient purpose-built high technology cGMP designed glasshouse (currently under construction)
  • High-quality manufacturing in our fully licensed volatile and non-volatile extraction facility
  • In house, state-wide compliant distribution of Sunniva branded products
  • Highly experienced management team assembled in California
  • A Board of Directors with a proven track record for creating significant shareholder value both in the healthcare and biotech industries

“Our team is committed to improving the lives of as many patients as possible by providing access to safe, high-quality cannabis products and services at scale. We will achieve this by attracting better talent, embracing better standards, and implementing better business practices.”

—

Dr. Anthony (Tony) Holler, Founder and CEO

Better Leadership

Sunniva’s Management Team

Dr. Anthony Holler

Chairman and CEO

Dr. Anthony (Tony) Holler is the former CEO and co-founder of ID Biomedical, acquired in 2015 by Glaxo Smith Kline for $1.7 billion, and former Chairman of Corriente Resources Inc., sold for approximately $700 million to CRCC-Tongguan Investment Co. Tony is the current Chairman of CRH Medical Corp., a publicly traded company and serves as Sunniva’s Chief Executive Officer. His expertise includes strategic planning, mergers and acquisitions, and financing, with a singular focus on increasing shareholder value.

Kevin Wilkerson

President of Sunniva Inc.; CEO and President, Sun CA Holdings, Inc.

Kevin is responsible for Sunniva's California operations. He joined Sunniva in November 2018 as the Chief Operating Officer of Sun CA Holdings, as part of Sunniva's acquisition of LTYR Logistics, LLC, a California based distribution company where he was CEO. Wilkerson's interest in business led him to complete a Harvard Master's degree and lead numerous successful private enterprises. He has been involved in the cannabis space since 2014, focused on providing operational excellence, distribution logistics and technology expertise to the industry. Mr. Wilkerson is a high-energy and results-driven leader who recognizes that focus, communication, collaboration and anticipation are critical to successful execution.

David Lyle

Chief Financial Officer

David Lyle joined Sunniva in June 2019 as Chief Financial Officer and will be responsible for all the administrative, financial and risk management operations of the Company.  Before joining Sunniva Mr. Lyle was senior vice president, chief financial officer, treasurer and secretary of Maxwell Technologies, Inc. a global leader in the development and manufacture of innovative, cost-effective energy storage and power delivery solutions. Before joining Maxwell, David has held the chief financial officer position at several public and private companies including Entropic Communications, RF Magic, Zyray Wireless and Mobilian Corp.  David holds a bachelor’s degree in business from the University of Southern California, a master of business administration from Arizona State University, and a master in international management from the Garvin School of International Management, Thunderbird.

Duncan Gordon

Chief Operating Officer

Duncan is the former head of manufacturing and supply chain management at Kudu Industries. With over 25 years of experience as a manufacturing and supply chain expert, he has led various teams and large-scale projects focused on engineering, procurement, logistics, production and distribution.

Better Governance

Sunniva’s Board Of Directors

Dr. Anthony Holler

Chairman and CEO

Dr. Anthony (Tony) Holler is the former CEO and co-founder of ID Biomedical, acquired in 2015 by Glaxo Smith Kline for $1.7 billion, and former Chairman of Corriente Resources Inc., sold for approximately $700 million to CRCC-Tongguan Investment Co. Tony is the current Chairman of CRH Medical Corp., a publicly traded company and serves as Sunniva’s Chief Executive Officer. His expertise includes strategic planning, mergers and acquisitions, and financing, with a singular focus on increasing shareholder value.

Todd R. Patrick

Lead Director (Independent)

Mr. Todd Patrick is the President and CEO of C3J Therapeutics, a Los Angeles-based biotechnology company focused on infectious disease drug development. Since joining C3J, Mr. Patrick has raised over $125 million in equity capital for the company. Prior to joining C3J, Mr. Patrick served as President and COO of ID Biomedical after the company elected in 1998 to exit its core diagnostic business to focus exclusively on vaccines. Mr. Patrick was the first employee of ID Biomedical’s vaccine business (“ID Vaccine”) in 1994 and remained at ID Biomedical until its acquisition by GlaxoSmithKline in 2005. Mr. Patrick is a member of the board of C3J, CRH Medical, and Vaxent Vaccines, LLC. He holds an MBA in finance and is a member of the Governance and Nominating Committee, Compensation Committee, and Chair of the Audit Committee of CRH Medical.

Norm Mayr

Director (Independent)

Norm Mayr is a recently retired (2016) Audit Partner having spent 38 years in public practice with KPMG. He was the Risk Management and Professional Practice Partner for the Greater Vancouver Area practice of KPMG for the most recent 18 years of his career. In this role, Norm was consulted regularly on complex financial reporting, accounting, audit, and securities issues. Norm has extensive experience in the mining, forestry, technology, retail and industrial markets sectors and he served as lead partner on many of KPMG’s largest multinational clients in these industries. He was a founding member of the CICA Accounting Standards Board and a member of the Canadian Advisory Group to the International Accounting Standards Committee.

Ian Webb

Director (Independent)

Former director of ID Biomedical and current director of CRH Medical Corp. Also, former senior corporate law partner of Borden Ladner Gervais LLP, one of Canada’s largest law firms, whose practice encompassed mergers and acquisitions as well as corporate and securities law with an emphasis on the legal requirements of public companies and their boards.

Luke Stanton

Director

Luke Stanton is an attorney and founder of the Frontera Law Group, a leading firm in the state of California focused on issues related to medical cannabis, which represents a host of quality cannabis companies, brands, products and ancillary service providers. Luke is also a general partner at Skytree Capital Partners, a Nevada-based private equity firm focused on the legal cannabis space. He has been featured in Financial Times Magazine, the National Marijuana News, mg Magazine, Cannabis Industry Journal, MJINews, LEFAIR Magazine and Merry Jane, and has made speaking appearances at numerous cannabis and investment conferences, summits and events across the country.

Michael Barker

Director

Founder of Barker Pacific Group, a firm of experienced real estate professionals active in the acquisition, development, construction management, and asset management of major commercial projects. Founded in 1983, the company specializes in the development and acquisition of institutional-quality office, industrial, and residential projects. As a developer, BPG has completed, developed, or redeveloped in excess of $2.5 billion in commercial projects. The company enjoys close relationships with major corporate and institutional partners who commend the Barker Pacific Group management team's commitment to excellence, entrepreneurial vision, business acumen, and personal integrity.